Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio

ORLANDO, Fla., March 30, 2017 -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal^TM, its proprietary form of lower-dose naltrexone, today announced it has filed three new patent applications in the US in the last four months with the latest being the Company's PTC patent for Method for Sustained Immune Response filed March 23, 2017.

"These applications reflect a further strengthening of our intellectual property assets around Lodonal,” notes Noreen Griffin, CEO of Immune Therapeutics. “While we believe our intellectual property (IP) portfolio is quite robust, these patents are expected to further strengthen our IP portfolio in terms of in the US and globally.”

The Patient Cooperation Treaty (PCT) patent application, Method for Sustained Immune Response, is based on clinical evidence showing that difference between immediate release lower dose naltrexone (Lodonal) and slow or extended release naltrexone. In a phase 2 trial the immediate release form Lodonal acts as an immunomodulator. The immediate release form may improve clinical outcomes in HIV/AIDS, cancer and a range of other conditions when used as a standalone treatment, or when used as a combination therapy in addition to standard of care. Improved outcomes may include the potential to control disease activity in patients. “Our claims in this application are based on over sixty clinical trials using low-dose naltrexone, Lodonal,” notes CEO Griffin.

Immune Therapeutics also filed the application - Methods and Compositions Useful for Treating Cancer. We developed the combinational stimulant (CS) and based on clinical evidence; with all approved drugs. The composition of CS contains the following components: (1) Thymosin, (2) Immune RNA, (3) Astragalus polysaccharide, (4) Transfer factor, (5) Utilins, (6) Polysaccharide of BCG, (7) Letinous edodes polysaccharide and (8) Manose polysaccharides-peptide, (9) Ubenimex, (10) SuperantigenA, (11) Met and (12) enkelphine.  The patent is supported by results in patients as part of a treatment program in conjunction with Professor Shan and the China Medical School.

The final patent application is Method for Treating and Preventing Protozoal Infections.  The patent relates to methods of treating and preventing protozoal infections by administering immediate release low dose naltrexone, preferably as a single oral tablet, capsule, liquid, rectal suppository, sublingual film or cream dose of naltrexone, either alone or in combination with one or more anti-protozoal agents. The compound has been tested successfully in preclinical safety studies, with no side effects detected so far. The company intends to run clinical trials for the treatment of malaria in 2017. Lodonal targets the ability of malaria parasites to replicate. Malaria is a highly infectious, mosquito-transmitted disease that kills nearly 600,000 people worldwide each year, mostly children under 5 years old living in sub-Saharan Africa. Nearly 200 million cases of malaria are reported annually, and about 3 billion people are at risk of malaria in 97 countries.

About Immune Therapeutics, Inc.

Immune Therapeutics, Inc. (OTCQB:IMUN) is a clinical-stage biopharmaceutical company developing its proprietary version of lower-dose naltrexone, Lodonal, as standalone and conjunctive therapy in patients with a wide variety of conditions including HIV/AIDS, autoimmune diseases, cancer, neurodegenerative conditions and other inflammatory conditions. Lodonal is a novel compound with a unique mechanism of action and has clinical data on over 400 patients in several clinical studies. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint.

Forward-Looking Statements

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Investor/Media Contact:
Brandon Thompson
Investor Relations Partners
Phone: 844-565-5665
[email protected]